Hero background Hero background

Targeting Disease
at the Nuclear Pore

Discover Now
About art top About art bottom

About Karyopharm

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Read more
Publications art top Publications art bottom


Scientific Papers, Posters and Presentations on Karyopharm pipeline compounds


Selective inhibitors of nuclear

Mendonca J (1), Sharma A (1), Kim HS (2), Hammers H (2), Meeker A

Novel Small Molecule XPO1/CRM1

Yang J (1), Bill MA (1), Young GS (2), La Perle K (3), Landesman

Posters & Presentations

CRM1 As a New Therapeutic Target

Yuankai Shi, MD, PhD*, Jianfei Wang, PhD*, Xiaohong Han, PhD*, Ningning

Quantification of Exportin-1 (XPO1)

Marsha Crochiere, Boris Klebanov, Erkan Baloglu, Ori Kalid, Trinayan

+ Visit Archive
Pipeline widget background Pipeline widget background


Our Drug Candidates: SINE™ Compounds and PAK4 Inhibitors

View Pipeline

Stock Quote (KPTI)

Investor Information
Stock Quote loader

Service temporary unavailable

Previous Close
Day High
Day Low
52-Week High
52-Week Low